Sarepta Therapeutics (SRPT) Misses Q2 EPS by 7c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
August 2, 2022 4:06 PM EDT-Â Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million
-Â Net product revenues for the second quarter 2022 totaled $211.2 million, a 49% increase over the same quarter of prior year
-Â Â Increased full-year total revenue and net product revenue guidance to a range of $905-$920 million and $825-$840 million, respectivelyÂ
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the... More
